Biomarkers for predicting response to checkpoint inhibitors

JP7765393B2Active Publication Date: 2025-11-06CHUGAI PHARMA CO LTD
11 Cites 0 Cited by

Patent Information

Application Number
JP2022548860
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-19
Filing Date
2021-03-19
Publication Date
2025-11-06
Estimated Expiration
2041-03-19

Smart Images

  • Figure 0007765393000001
    Figure 0007765393000001
  • Figure 0007765393000002
    Figure 0007765393000002
  • Figure 0007765393000003
    Figure 0007765393000003
Patent Text Reader

Abstract

The present invention provides a biomarker for predicting response to checkpoint inhibitors. The inventors demonstrate that PD-1 / PD-L1 inhibitors exert antitumor activity against tumors with low levels of PD-L1 expression and an immune desert phenotype by blocking PD-L1 in lymph nodes. The present invention provides a novel combination of an intratumoral marker for antigen cross-presenting cells and a T cell chemokine, which is expected to be a superior efficacy predictive biomarker compared to existing methods.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Predicting response to PD-1 axis inhibitors

    JP2019536433A

  • Biomarkers and methods of treating PD-1 and PD-l1 related conditions

    US20150071910A1

  • Predicting response to epigenetic drug therapy

    WO2015120382A1

  • Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

    WO2016168133A1

  • Gene signature for immune therapies in cancer

    WO2017013436A1